• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

Pentamidine Amidoxime (CAS No. 130349-07-4): A Comprehensive Overview of Its Applications and Recent Research Findings

Pentamidine Amidoxime, with the chemical identifier CAS No. 130349-07-4, is a compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound, known for its unique structural and functional properties, has found applications in various therapeutic areas, particularly in the treatment of infectious diseases and as a potential candidate for drug development. This article aims to provide an in-depth exploration of Pentamidine Amidoxime, focusing on its chemical structure, mechanisms of action, clinical applications, and the latest research developments.

The chemical structure of Pentamidine Amidoxime is characterized by a complex arrangement of nitrogen-containing heterocycles and functional groups. The presence of the amidoxime moiety contributes to its reactivity and interaction with biological targets. This structural feature has been pivotal in its development as an antimicrobial agent, particularly against a range of pathogens that pose significant challenges to modern medicine.

In recent years, Pentamidine Amidoxime has been studied extensively for its potential in combating drug-resistant infections. One of the most notable areas of research has been its application in the treatment of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). Traditional antitubercular drugs have faced challenges due to the emergence of multidrug-resistant TB strains. Studies have shown that Pentamidine Amidoxime exhibits promising activity against both drug-susceptible and drug-resistant TB strains, making it a valuable addition to the armamentarium against TB.

Furthermore, research has highlighted the compound's efficacy in targeting fungal infections, particularly those caused by Candida species. Fungal infections are increasingly prevalent due to the rise in immunocompromised patients, and there is a critical need for novel antifungal agents. The ability of Pentamidine Amidoxime to inhibit fungal growth and biofilm formation has been demonstrated in several preclinical studies, suggesting its potential as a therapeutic option for severe fungal infections.

The mechanism of action of Pentamidine Amidoxime involves multiple pathways that contribute to its antimicrobial effects. One key mechanism is its ability to disrupt bacterial cell membranes by interacting with lipid components, leading to increased permeability and cell death. Additionally, it has been shown to interfere with essential bacterial metabolic processes, further contributing to its antibacterial activity.

In terms of clinical applications, Pentamidine Amidoxime has been investigated for its potential use in treating other infectious diseases as well. For instance, studies have explored its efficacy against Pseudomonas aeruginosa, a Gram-negative bacterium known for its resistance to multiple antibiotics. The compound's ability to overcome bacterial resistance mechanisms makes it a promising candidate for treating infections caused by such pathogens.

Recent research has also delved into the pharmacokinetic properties of Pentamidine Amidoxime. Understanding how the compound is absorbed, distributed, metabolized, and excreted is crucial for optimizing its therapeutic use. Studies have indicated that the compound exhibits moderate bioavailability and a relatively long half-life, which could allow for less frequent dosing regimens compared to existing antimicrobial agents.

The development of new drug formulations based on Pentamidine Amidoxime is another area of active research. Researchers are exploring various delivery systems, such as nanoparticles and liposomes, to enhance the compound's bioavailability and target specificity. These advanced formulations could improve therapeutic outcomes while minimizing side effects.

Safety profile considerations are also essential when evaluating the clinical potential of any pharmaceutical compound. While Pentamidine Amidoxime shows promise in treating infectious diseases, it is important to assess its potential side effects and toxicities. Preliminary studies have indicated that the compound can cause some adverse effects, such as hypoglycemia and liver enzyme elevations. However, further research is needed to fully understand these effects and develop strategies to mitigate them.

The future direction of research on Pentamidine Amidoxime includes exploring its potential in combination therapies with other antimicrobial agents. Combination therapy is often employed to address drug resistance and improve treatment outcomes. By studying how Pentamidine Amidoxime interacts with other drugs at both the molecular and clinical levels, researchers can identify synergistic effects that could enhance overall therapeutic efficacy.

In conclusion, Pentamidine Amidoxime (CAS No. 130349-07-4) represents a significant advancement in the field of antimicrobial chemotherapy. Its unique chemical structure and multifaceted mechanisms of action make it a versatile tool against various infectious agents. The latest research findings underscore its potential in treating drug-resistant TB, fungal infections, and other challenging pathogens. As ongoing studies continue to unravel the complexities of this compound's pharmacology and clinical applications, it holds great promise for addressing global health challenges related to infectious diseases.

• 104-32-5(Propamidine)
• 3748-77-4(Bunamidine)
• 17353-82-1(4,4'-Oxybis(N-hydroxybenzimidamide))
• 15535-98-5(4-Hydroxybenzimidamide)
• 100-33-4(4-{5-(4-carbamimidoylphenoxy)pentyloxy}benzene-1-carboximidamide)
• 125880-79-7(Benzenecarboximidamide,4,4'-[1,3-propanediylbis(oxy)]bis[3-amino-)
• 124076-65-9(Benzenecarboximidamide,4,4'-[1,3-propanediylbis(oxy)]bis[3-methoxy-)
• 104192-47-4(1,6-Hexanedione,1,6-bis[4-(hexyloxy)phenyl]-, dioxime (9CI))
• 121324-49-0(Benzenecarboximidamide,4,4'-[1,4-butanediylbis(oxy)]bis-, hydrochloride (9CI))
• 145259-49-0(N'-hydroxy-4-propoxybenzenecarboximidamide)